Clinical Trial Search

Primary: PC 20 Methacholine (Provocative Concentration of Methacholine Causing 20 % Fall in FEV1(Forced Expiratory Volume) — 1.546; 2.163; 1.673; 2.079 Ratio

Primary: Annualized Relapse Rate [ARR]: Poisson Regression Estimates — 0.539; 0.370; 0.369 relapses per year — p=0.0005

Primary: Core Treatment Period: Overview of Failures — 53; 42; 44; 56 participants

Primary: Number of Participants With Prostate Cancer — 473; 432; 437; 416 participants — p=< .01

Primary: Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1 — 70.0; 68.3 Percentage of Participants — p=0.667

Primary: The Average Intravaginal Ejaculatory Latency Time (IELT) at Week 12 — 1.1; 3.4; 1.1; 5.2 minutes — p=<0.001

Primary: Percentage of Treatment Responders — 21.3; 17.2 Percentage of Patients

Primary: Number of Participants With Psoriasis Area and Severity Index (PASI) Score of 75 Percent or Above at Week 12 — 15; 273; 311 Participants — p=<0.001

Primary: Trough FEV1 (L) at 28 Weeks on Treatment — 1.422; 1.356 Liters

Primary: Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40) — 48.1; 25.6…

Primary: Trough FEV1 (L) at 28 Weeks on Treatment — 1.220; 1.162 Liters

Primary: The Number of Patients Who Described Their Premature Ejaculation (PE) as At Least "Slightly Better" in Response to Dapoxetine Treatment — 228 Patients

Primary: Mean Interproximal Lobene Modified Gingival Index Between the Brushing Only Group and the Brushing + Flossing Group — 2.11; 1.87 units on a scale — p=0.001

Primary: Overall Survival — 83; 79; 79 percentage of patients alive

Primary: Treatment Satisfaction Subscales (Interference, Regimen Adaptation, Role Limitations, Sensory Impact, Regimen Difficulties, Burden, Hassle, Regimen Management, and…